AXGN logo

AXOGEN INC

AXGNNASDAQ
πŸ† #1502 by market capEarnings Feb 22 Β· PostUS Equity
$55.75β–Ό $0.60 (βˆ’1.06%)
Market closed Β· at close
πŸ””
Track AXGN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.1%
7dβ–Ό 0.3%
14dβ–² 11.7%
30dβ–² 46.5%
ytdβ–² 70.5%
1yβ–² 107.6%
🏦Market Cap
$3.33B
Small Cap
πŸ“ˆRevenue Growth (YoY)
20.2%
Healthy
πŸ“ŠGross Margin
74.2%
High
πŸ’΅FCF Margin
6.1%
Moderate
βš–οΈP/S Ratio
12.5x
Elevated
Otter Score
84
Strong

Trading Snapshot

Day Range
$55.03 – $56.91
52-Week Range
$26.92 – $59.72
Volume (shares)
876,067
Avg Volume (shares)
β€”
Shares Outstanding
59.7M
Next Earnings
2027-02-22

Fundamentals Snapshot

Annual Revenue
$225M
Last Q Revenue
$76M
P/E Ratio
-85.8
P/S Ratio
12.5x
EPS (TTM)
$-0.58
Dividend Yield
0.00%
Dilution (1yr)
βˆ’2.4%
AXGN logo

AXOGEN INC

AXGN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$225Mβ–² +20.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
74.3%β–Ό βˆ’1.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$8Mβ–² +138.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$3Mβ–Ό βˆ’26763.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
46.9Mβ–Ό βˆ’2.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$32Mβ–² +$9M YoY
StockOtter Β· stockotter.space

About AXOGEN INC

AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
84/100

Analyst Ratings

β“˜
Consensus
Buy
17 analysts
Strong Buy5
Buy11
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.